Nautilus Biotechnology, Inc.

Good day and thank you for standing by. Welcome to Nautilus Q4 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message, advise your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Carrie Mendeville, Investor Relations. Please go ahead.

Thank you. Earlier today, Nautilus released financial results for the quarter and full year ended December 31st, 2023. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investorrelations at nautilus.bio. Joining me today from Nautilus are Sujil Patel, co-founder and CEO, Parag Malik, co-founder and chief scientist, and Anna Mowery, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Visual information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, February 28, 2024. With that, I'll turn the call over to Sujal.

Thanks, Keri. Good morning, and thank you to everyone for joining us today. This morning, we'll share our results for the fourth quarter and full year 2023 and provide an update on recent activities. But first, I want to thank our employees, our partners, and our investors. Creating a platform capable of enabling researchers to explore the mysteries and the potential of the proteome is very much a team effort. It requires strong alignment up and down the organization, vision, persistence, and an unwavering commitment to our goal of improving human health. I'm grateful for the extraordinary work the entire team did in 2023 and for how they've kicked off 2024 stronger than ever. We recognize that we're tackling a big, hard problem that has never been successfully addressed. And armed with the learnings of last year and years prior, We now have greater clarity about what remains to be done to deliver what we believe will be a game-changing platform to the market. We enter 2024 more energized than ever, focused on the good that we anticipate our platform can do, and confident in our ability to get there. When I reflect on 2023, I see it as a year of accomplishment and of foundational progress. Progress that will continue to build momentum for Nautilus as we move through 2024 and towards the planned launch of our podium analysis platform in 2025. You'll hear more details about specific R&D progress from Parag in just a few minutes and more context from me around the revised launch timeframe a little later. But first, I want to reflect on what we continue to hear from potential customers and what I sense as I look across the market landscape. At a high level, I'm encouraged by a growing awareness among researchers about the role that proteomic data can play if easily and cost-effectively generated in augmenting other high-value biological datasets. More specifically, we continue to receive enthusiastic feedback from the researchers and partners with whom we've directly engaged. They recognize the inherent limitations of both traditional analysis methods and of emerging affinity-based and peptide sequencing methods. they clearly understand how critically important single molecule intact protein analysis, which only Nautilus is designed to deliver, will be to their expanded explorations of the proteome. We, and they, envision a day when their ability to explore the entire proteome more thoroughly will net fundamental advances in basic biological research, enabling researchers to make a substantial impact on the efficiency, and cost effectiveness of biomarker discovery and drug development. While the desire on the part of researchers to finally have a breakthrough in the availability and cost of valuable proteomic data is not new, what is new is the potential of actually delivering on that dream. That is fueling the imagination of researchers to think beyond what has been possible and towards the idea of what could be possible. This is a truly exciting time to be on the front lines of proteomic innovation. With that, let me now turn the call over to Parag for an update on our progress on the R&D front.